Skip to main content

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

*August 2020*

The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. Resistance mutations in our genes can lead to resistance to specific treatments, meaning that drugs no longer work. Patients in the current study all initially received afatinib treatment before they developed a certain resistance mutation in the EGFR gene, called T790M. Patients then started osimertinib treatment. The study aimed to identify for how long patients received treatment and for how long patients survived after their first dose of afatinib. Overall, 204 patients were included. Median overall time on treatment (afatinib and osimertinib) was 27.7 months. Median overall survival was 37.6 months. This study showed that afatinib followed by osimertinib treatment was effective in patients with NSCLC with EGFR mutations developing T790M resistance mutations on initial afatinib treatment. Read more.